Simplex Trading’s Cartesian Therapeutics RNAC Stock Holding History

Simplex Trading’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.08K	Hold	500	–	–	﹤0.01%	8170
2025 Q4	$3.6K	Buy	+500	New	+$4.04K	﹤0.01%	7595
2022 Q4	–	Sell	-1,787	Closed	-$87K	–	10224
2022 Q3	$87K	Sell	1,787 -20	-1%	-$1.1K	﹤0.01%	5716
2022 Q2	$71K	Buy	1,807 +1,674	+1,259%	+$49.6K	﹤0.01%	6024
2022 Q1	$4K	Sell	133 -157	-54%	-$9.82K	﹤0.01%	9589
2021 Q4	$28K	Sell	290 -27	-9%	-$2.9K	﹤0.01%	8000
2021 Q3	$41K	Hold	317	–	–	﹤0.01%	7762
2021 Q2	$39K	Buy	317 +313	+7,825%	+$37.3K	﹤0.01%	7950
2021 Q1	$47K	Buy	+4	New	+$497	﹤0.01%	6701
2020 Q3	–	Sell	-3	Closed	-$21K	–	8387
2020 Q2	$21K	Buy	+3	New	+$272	﹤0.01%	6191
2020 Q1	–	Hold	0	–	–	–	7402
2019 Q2	–	Sell	-3	Closed	-$18K	–	7674
2019 Q1	$18K	Buy	+3	New	+$190	﹤0.01%	5788
2018 Q4	–	Hold	0	–	–	–	6777
2018 Q2	–	Hold	0	–	-$2K	–	7812
2018 Q1	–	Hold	0	–	–	–	5331

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simplex Trading's RNAC Position: Q4 2023 in Review

Simplex Trading sold out of Cartesian Therapeutics (RNAC) in Q4 2023, closing a stake of 7 shares — an estimated $209 sold.

Simplex Trading first reported a position in RNAC in Q1 2018 and held it in 17 quarters. The position peaked at $243K in Q1 2021. 80 funds tracked by Wall St. Rank hold RNAC as of Q4 2023.

Simplex Trading reported no remaining Cartesian Therapeutics position as of Q4 2023 after selling out during the quarter.
Simplex Trading sold 7 Cartesian Therapeutics shares in Q4 2023, an estimated $209.
Simplex Trading first reported a position in Cartesian Therapeutics in Q1 2018 and held it in 17 quarters.
Simplex Trading's Cartesian Therapeutics position peaked at $243K in Q1 2021.
80 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2023.

Based on Simplex Trading's 13F filing for Q4 2023, filed 2 Feb 2024.